Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results

Highlights

• Bexmarilimab, a novel Clever-1 inhibitor, combined with azacitidine, demonstrated a manageable safety profile with no dose-limiting toxicities in high-risk myelodysplastic syndrome (MDS) and relapsed/refractory acute myeloid leukaemia (AML).
• The recommended phase 2 expansion dose of bexmarilimab was determined as 6.0 mg/kg weekly, with promising objective response rates (45%).
• Adverse event rates were consistent with known profiles of azacitidine, and no new safety signals emerged.

Study Background and Disease Burden